Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial
- 22 December 2023
- journal article
- research article
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 80, 27-35
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Serotonin and CGRP in MigraineAnnals of Neurosciences, 2012
- Hallucinogen Rating Scale (HRS) - Versão brasileira: tradução e adaptação transculturalArchives of Clinical Psychiatry (São Paulo), 2011
- The Hallucinogen N,N -Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor RegulatorScience, 2009
- Human hallucinogen research: guidelines for safetyJournal of Psychopharmacology, 2008
- Development of a rational scale to assess the harm of drugs of potential misuseThe Lancet, 2007
- Evaluation of a vaporizing device (Volcano®) for the pulmonary administration of tetrahydrocannabinolJournal of Pharmaceutical Sciences, 2006
- Psychological Effects of (S)-Ketamine and N,N-Dimethyltryptamine (DMT): A Double-Blind, Cross-Over Study in Healthy VolunteersPharmacopsychiatry, 2005
- Dose-Response Study of N,N-Dimethyltryptamine in HumansArchives of General Psychiatry, 1994
- Dose-Response Study of N,N-Dimethyltryptamine in HumansArchives of General Psychiatry, 1994
- Dimethyltryptamin: Its metabolism in man; the relation of its psychotic effect to the serotonin metabolismCellular and Molecular Life Sciences, 1956